SCHEMBL810307

SCHEMBL810307

N#Cc1cccc(COc2ccc(Sc3ccc(O)cc3)c(Nc3ncnc4ncccc34)c2)c1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PIM1 P11309 1/20 0.52
AKT2 P31751 1/20 0.52
MAOB P27338 3/20 0.38
MAOA P21397 2/20 0.38
CYP4F2 P78329 1/20 0.38
CYP4A11 Q02928 1/20 0.38
GRM5 P41594 1/20 0.37
FFAR1 O14842 1/20 0.37
FFAR4 Q5NUL3 1/20 0.37
EGFR P00533 4/20 0.37
ERBB2 P04626 2/20 0.37
ABCG2 Q9UNQ0 3/20 0.36
PPIA P62937 1/20 0.36
CYP19A1 P11511 1/20 0.36
CYP11B1 P15538 1/20 0.36
CYP11B2 P19099 1/20 0.36
MEN1 O00255 1/20 0.34
MAPT P10636 1/20 0.34
KDR P35968 1/20 0.34
KMT2A Q03164 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL810225 0.92 PIM1 (0.53) PIM1AKT2MAOBMAOACYP4F2
SCHEMBL810757 0.88 PIM1 (0.68) PIM1AKT2MAOBMAOACYP4F2
SCHEMBL810273 0.88 PIM1 (0.60) PIM1AKT2EGFRERBB2MEN1
SCHEMBL810060 0.88 PIM1 (0.58) PIM1AKT2MAOBMAOAGRM5
SCHEMBL810912 0.88 PIM1 (0.58) PIM1AKT2MAOBMAOAEGFR
SCHEMBL810939 0.88 PIM1 (0.54) PIM1AKT2MAOBMAOAEGFR
SCHEMBL810397 0.87 PIM1 (0.55) PIM1AKT2MAOBEGFRERBB2
SCHEMBL810897 0.86 PIM1 (0.55) PIM1AKT2MAOBMAOAMEN1
SCHEMBL810073 0.86 PIM1 (0.55) PIM1AKT2MAOBMAOACYP4F2
SCHEMBL4375932 0.84 PIM1 (0.55) PIM1AKT2MAOBMAOAGRM5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1971611-B1 ANTI-VIRAL COMPOUNDS ABBOTT LAB (US) 2012-10-10 EP disclosed
EP-2345652-A1 Antiviral compounds Abbott Laboratories (US) 2011-07-20 EP disclosed
US-7915411-B2 Anti-viral compounds ABBOTT LABORATORIES (US) 2011-03-29 US disclosed
EP-1971611-A1 ANTI-VIRAL COMPOUNDS Abbott Laboratories (US) 2008-09-24 EP disclosed
US-20070197558-A1 ANTI-VIRAL COMPOUNDS ABBVIE INC. 2007-08-23 US disclosed
WO-2007081517-A2 ANTI-VIRAL COMPOUNDS ABBOTT LABORATORIES (US) 2007-07-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070197558-A1 ANTI-VIRAL COMPOUNDS HAVCR2, MAVS, EIF2AK2 PIM1 2963/4885AKT2 3903/4885MAOB 3352/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.